CoChat

Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Lymphocytes extracted from freshly resected melanomas can be expanded in vitro and can often mediate specific lysis of autologous tumor cells but not allogeneic tumor or autologous normal cells. We treated 20 patients with metastatic melanoma by means of adoptive transfer of these tumor-infiltrating lymphocytes and interleukin-2, after the patients had received a single intravenous dose of cyclophosphamide. Objective regression of the cancer was observed in 9 of 15 patients (60 percent) who had not previously been treated with interleukin-2 and in 2 of 5 patients (40 percent) in whom previous therapy with interleukin-2 had failed. Regression of cancer occurred in the lungs, liver, bone, skin, and subcutaneous sites and lasted from 2 to more than 13 months. Toxic effects of interleukin-2 occurred, although the treatment course was short (five days); these side effects were reversible. It appears that in patients with metastatic melanoma, this experimental treatment regimen can produce higher response rates than those achieved with interleukin-2 administered alone or with lymphokine-activated killer cells. It is too early to determine whether this new form of immunotherapy can improve survival, but further trials seem warranted.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm198812223192527

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 7

  1. Rosenberg, 1985, JNCI, 75, 595
  2. Lafreniere, 1985, Cancer Res, 45, 3735
  3. Rosenstein, 1984, Cancer Res, 44, 1946
  4. Spiess, 1987, JNCI, 79, 1067
  5. Itoh, 1986, Cancer Res, 46, 3011
  6. Rabinowich, 1987, Cancer Res, 47, 173
  7. Belldegrun, 1988, Cancer Res, 48, 206

Cited by

See all 2,389

Metadata

Authors
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J. P., & White, D. E.
Affiliations
  • National Cancer Institute (US)
  • National Cancer Institute (MY)
  • DuPont (United States) (US)
  • National Institutes of Health (US)
Venue
New England Journal of Medicine
Published
1988-12-22
Volume
319
Issue
25
Pages
1676-1680
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2335365056
Cited by
2,389
References
24
Citations by year
2026: 76 · 2025: 95 · 2024: 113 · 2023: 89 · 2022: 106 · 2021: 113 · 2020: 120 · 2019: 86 · 2018: 83 · 2017: 69 · 2016: 67 · 2015: 51 · 2014: 33 · 2013: 40 · 2012: 34
FWCI
30.13
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
metastatic melanoma, tumor-infiltrating lymphocytes, interleukin-2, adoptive immunotherapy, cyclophosphamide, lymphokine-activated killer cells, tumor regression
MeSH terms
Adult, Cells, Cultured, Combined Modality Therapy, Cyclophosphamide, Female, Humans, Immunotherapy, Interleukin-2, Lymphocytes, Male, Melanoma, Middle Aged, Neoplasm Metastasis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma. https://app.cochat.ai/papers/10.1056/nejm198812223192527
The paper
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J. P., & White, D. E. (1988). Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma. New England Journal of Medicine. https://doi.org/10.1056/nejm198812223192527

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.